La radiologia medica

, Volume 117, Issue 1, pp 19–28

Role of cardiac MRI in evaluating patients with Anderson-Fabry disease: assessing cardiac effects of long-term enzyme replacement therapy

  • G. Messalli
  • M. Imbriaco
  • G. Avitabile
  • R. Russo
  • D. Iodice
  • L. Spinelli
  • S. Dellegrottaglie
  • F. Cademartiri
  • M. Salvatore
  • A. Pisani
Cardiac Radiology / Cardioradiologia

Abstract

Purpose

Anderson-Fabry disease is a multisystemic disorder of lipid metabolism secondary to X-chromosome alterations and is frequently associated with cardiac manifestations such as left ventricular (LV) hypertrophy, gradually leading to an alteration in cardiac performance. The purpose of this study was to monitor, using magnetic resonance imaging (MRI), any changes produced by enzyme replacement therapy with agalsidase beta at the cardiac level in patients with Anderson-Fabry disease.

Materials and methods

Sixteen (ten men, six women) patients with genetically confirmed Anderson-Fabry disease underwent cardiac MRI before starting enzyme replacement therapy (baseline study) and after 48 months of treatment with agalsidase beta at the dose of 1 mg/kg (follow-up study).

Results

After 48 months of treatment, a significant reduction in LV mass and wall thickness was observed: 187±59 g vs. 149±44 g, and 16±3 mm vs. 13±3 mm, respectively. A significant reduction in T2 relaxation time was noted at the level of the interventricular septum (81±3 ms vs. 67±7 ms), at the apical level (80±8 ms vs. 63±6 ms) and at the level of the lateral wall (82±8 ms vs. 63±10 ms) (p<0.05). No significant variation was observed in ejection fraction between the two studies (65±3% vs. 64±2%; p>0.05) (mean bias 1.0); however, an improvement was noted in the New York Heart Association (NYHA) class of the majority of patients (12/16) (p<0.05).

Conclusions

In patients with Anderson-Fabry disease undergoing enzyme replacement therapy with agalsidase beta, MRI documented a significant reduction in myocardial T2 relaxation time, a significant decrease in maximal myocardial thickness and in total LV mass. MRI did not reveal significant improvements in LV global systolic function; however, improvement in NYHA functional class was noted, consistent with improved diastolic function.

Keywords

MRI Anderson-Fabry disease Cardiac T2 relaxation time 

Ruolo della RM cardiaca nello studio dei pazienti con malattia di Anderson-Fabry: valutazione degli effetti cardiaci della terapia enzimatica sostitutiva a lungo termine

Riassunto

Obiettivo

La malattia di Anderson-Fabry è un disordine multi-sistemico del metabolismo lipidico, secondario ad una alterazione del cromosoma X ed è frequentemente associata a sintomi cardiaci come l’ipertrofia ventricolare sinistra, che gradualmente conduce ad una alterazione della performance cardiaca. Lo scopo di questo studio è stato di monitorare con risonanza magnetica (RM) i cambiamenti che la terapia enzimatica sostitutiva, con agalsidase beta, è in grado di indurre a livello cardiaco, nei pazienti affetti da malattia di Anderson-Fabry.

Materiali e metodi

Sedici pazienti (10 maschi, 6 donne) con diagnosi di malattia di Anderson-Fabry, geneticamente confermata, sono stati studiati con RM cardiaca, prima di iniziare la terapia enzimatica sostitutiva (studio basale) e dopo 48 mesi di terapia, con agalsidase beta alla dose di 1 mg/kg (follow-up).

Risultati

Dopo 48 mesi di terapia, si è osservata una significativa riduzione dei valori di massa e dello spessore di parete del ventricolo sinistro (VS): 187±59 g vs 149±44 g, e 16±3 mm vs 13±3 mm, rispettivamente. Una significativa riduzione del tempo di rilassamento T2 è stata osservata a livello del setto inter-ventricolare 81±3 ms vs 67±7 ms, a livello dell’apice 80±8 ms vs 63±6 ms ed a livello della parete laterale 82±8 ms vs 63±10 ms (p<0,05). Non sono state osservate variazioni significative nei valori di frazione d’eiezione tra i due studi (65±3% vs 64±2%; p>0,05) (bias medio 1,0), tuttavia si è osservato un miglioramento della classe secondo la New York Heart Association (NYHA) nella maggior parte dei pazienti studiati (12/16) (p<0,05).

Conclusioni

Nei pazienti affetti da malattia di Anderson-Fabry ed in terapia enzimatica sostitutiva con agalsidase beta, la RM documenta una significativa riduzione del tempo di rilassamento T2 miocardico, una significativa riduzione degli spessori massimi miocardici e della massa ventricolare totale sinistra. La RM non rileva un significativo miglioramento della funzionalità sistolica globale del ventricolo sinistro, tuttavia assistiamo ad un miglioramento della classe funzionale NYHA, compatibile con un miglioramento della funzionalità diastolica.

Parole chiave

RM Malattia di Anderson-Fabry Sintomi cardiaci Tempo di rilassamento T2 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References/Bibliografia

  1. 1.
    Nagueh SF (2003) Fabry disease. Heart 89:819–820PubMedCrossRefGoogle Scholar
  2. 2.
    Desnick RJ, Brady R, Barranger J, Collins AJ (2003) Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138:338–346PubMedGoogle Scholar
  3. 3.
    Hopkin RJ, Bissler J, Banikazemi M et al (2008) Characterization of Fabry disease in 352 paediatric patients in the Fabry Registry. Pediatr Res 64:550–555PubMedCrossRefGoogle Scholar
  4. 4.
    Linhart A, Magage S, Palecek T et al (2002) Cardiac involvement in Fabry disease. Acta Paediatr Suppl 91:15–20PubMedCrossRefGoogle Scholar
  5. 5.
    Kampmann C, Linhart A, Baehner F et al (2008) Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Int J Cardiol 130:367–373PubMedCrossRefGoogle Scholar
  6. 6.
    Eng CM, Guffon N, Wilcox WR et al (2001) Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry’s disease. N Engl J Med 345:9–16PubMedCrossRefGoogle Scholar
  7. 7.
    Schiffmann R, Kopp JB, Austin HA III et al (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285:2743–2749PubMedCrossRefGoogle Scholar
  8. 8.
    Wilcox WR, Banikazemi M, Guffon N et al (2004) Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75:65–74PubMedCrossRefGoogle Scholar
  9. 9.
    Weidemann F, Breunig F, Beer M et al (2003) Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 108:1299–1301PubMedCrossRefGoogle Scholar
  10. 10.
    Desnick RJ, Brady RO (2004) Fabry disease in childhood. J Pediatr 144:20–26Google Scholar
  11. 11.
    Moller AT, Jensen TS (2007) Neurological manifestations in Fabry’s disease. Nat Clin Pract Neurol 3:95–106PubMedCrossRefGoogle Scholar
  12. 12.
    Linhart A, Elliott PM (2007) The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart 93:528–535PubMedCrossRefGoogle Scholar
  13. 13.
    Branton M, Schiffmann R, Kopp JB (2002) Natural history and treatment of renal involvement in Fabry disease. J Am Soc Nephrol 13:139–143Google Scholar
  14. 14.
    Zarate YA, Hopkin RJ (2008) Fabry’s disease. Lancet 372:1427–1435PubMedCrossRefGoogle Scholar
  15. 15.
    Linhart A (2008) Treatment of Anderson-Fabry disease. Heart 94:138–139PubMedCrossRefGoogle Scholar
  16. 16.
    von Scheidt W, Eng CM, Fitzmaurice TF et al (1991) An atypical variant of Fabry’s disease with manifestations confined to the myocardium. N Engl J Med 324:395–399CrossRefGoogle Scholar
  17. 17.
    Weidemann F, Breunig F, Beer M et al (2005) The variation of morphological and cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 26:1221–1227PubMedCrossRefGoogle Scholar
  18. 18.
    Germain DP, Waldek S, Banikazemi M et al (2007) Sustained long-term stabilization after 54 months of algasidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 18:1547–1557PubMedCrossRefGoogle Scholar
  19. 19.
    Breunig F, Weidemann F, Strotmann J et al (2006) Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int 69:1216–1221PubMedCrossRefGoogle Scholar
  20. 20.
    Beer M, Weidemann F, Breunig F et al (2006) Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry’s cardiomiopathy. Am J Cardiol 97:1515–1518PubMedCrossRefGoogle Scholar
  21. 21.
    De Cobelli F, Esposito A, Belloni E et al (2009) Delayed-enhanced cardiac MRI for differentiation of Fabry’s disease from symmetric hypertrophic cardiomiopathy. AJR Am J Roentgenol 192:W97–W102PubMedCrossRefGoogle Scholar
  22. 22.
    Higgins CB, Herfkens R, Lipton MJ et al (1983) Nuclear magnetic resonance imaging of acute myocardial infarction in dogs: alterations in magnetic relaxation times. Am J Cardiol 52:184–188PubMedCrossRefGoogle Scholar
  23. 23.
    Imbriaco M, Spinelli L, Cuocolo A et al (2007) MRI characterization of myocardial tissue in patients with Fabry’s disease. AJR Am J Roentgenol 188:850–853PubMedCrossRefGoogle Scholar
  24. 24.
    Weidemann F, Niemann M, Breunig F et al (2009) Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 119:524–529PubMedCrossRefGoogle Scholar
  25. 25.
    Spinelli L, Pisani A, Sabbatini M et al (2004) Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry’s disease. Clin Genet 66:158–165PubMedCrossRefGoogle Scholar
  26. 26.
    Imbriaco M, Pisani A, Spinelli L et al (2009) Effects of enzyme replacement therapy in patients with Anderson-Fabry disease: a prospective long-term magnetic resonance imaging study. Heart 95:1103–1107PubMedCrossRefGoogle Scholar
  27. 27.
    Kovacevic-Preradovic T, Zuber M, Attenhofer Jost CH et al (2008) Anderson-Fabry disease: long-term echocardiographic follow-up under enzyme replacement therapy. Eur J Echocardiogr 9:729–735PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2011

Authors and Affiliations

  • G. Messalli
    • 1
    • 4
  • M. Imbriaco
    • 1
  • G. Avitabile
    • 1
  • R. Russo
    • 2
  • D. Iodice
    • 1
  • L. Spinelli
    • 3
  • S. Dellegrottaglie
    • 3
  • F. Cademartiri
    • 5
  • M. Salvatore
    • 1
  • A. Pisani
    • 2
  1. 1.Dipartimento di Scienze Biomorfologiche e FunzionaliUniversità degli Studi “Federico II”NapoliItaly
  2. 2.Dipartimento di NefrologiaUniversità degli Studi “Federico II”NapoliItaly
  3. 3.Dipartimento di Medicina Clinica e Scienze Cardiovascolari ed ImmunologicheUniversità degli Studi “Federico II”NapoliItaly
  4. 4.Istituto di Biostrutture e BioimmaginiCNRNapoliItaly
  5. 5.Azienda Ospedaliera-Universitaria di ParmaParmaItaly
  6. 6.NapoliItaly

Personalised recommendations